CME/CE

CME/CE

By ReachMDMedicine
Download on the App Store

CME/CE episodes

  • Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
    Host: Alan Venook, MD

    The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

    6 min
  • Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
    Host: Erica L. Mayer, MD, MPH

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    7 min
  • Management of HER2-Low MBC Following First-Line Disease Progression
    Host: Peter Schmid, FRCP, MD, PhD

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    8 min
  • Unmasking IgAN: From Suspicion to Timely Diagnosis
    Host: Jörg Latus, MD
    Guest: Chee Kay Cheung, MBCHB, MRCP, PHD

    Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a patient case study.

    20 min
  • Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
    Host: Peter Schmid, FRCP, MD, PhD

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    7 min
  • The Evolving Treatment Landscape for MBC: Emerging Therapies
    Host: William J. Gradishar, MD

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    11 min
  • Expert Viewpoint: Optimizing Breast Cancer Treatment
    Host: William J. Gradishar, MD
    Guest: Erica L. Mayer, MD, MPH
    Guest: Peter Schmid, FRCP, MD, PhD

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    19 min
  • First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
    Host: Sara Lonardi, MD

    The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

    5 min
  • Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
    Host: Sara Lonardi, MD

    The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

    6 min
  • Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
    Host: Erica L. Mayer, MD, MPH

    Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to provide the most accurate recommendations based on recent scientific evidence and drug approvals. This activity has been designed to review the current NCCN guidelines and the supporting data and explore best practices for selecting therapy based on these recommendations.

    Explore guideline-based strategies and clinical data to optimize guideline-adherent care for patients with CLL/SLL and MCL.

    6 min

About CME/CE

From the publisher's feed

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes,…